TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact

English

简体 English 繁体

About Us
Company Profile Mission Leadership
Senior Management Board of Directors Scientific Advisory Boards
Milestones Sustainability
Innovation
Discovery Translational Research Process Development Clinical Development Manufacturing
Products
Pipeline Core products
Osemitamab (TST001) TST002 TST003
Scientific Publications
Partnering
Investors
News & Events
Press Release In The News Events

About Us
Company Profile Mission Leadership
Senior Management Board of Directors Scientific Advisory Boards
Milestones Sustainability
Innovation
Discovery Translational Research Process Development Clinical Development Manufacturing
Products
Pipeline Core products
Osemitamab(TST001) TST002 TST003
Scientific Publications
Partnering
Investors
News & Events
Press Release In The News Events
Careers
Life in Transcenta Job Opportunity

Contact
简体
English
繁体

TST105

FGFR2b Bi-Specific

Target:: FGFR2b Bi-Specific

Indication:: Solid tumors

Project Status:: Preclinical

© 2019 TRANSCENTA HOLDING ALL RIGHTS RESERVED.

Copyright Declaration
Privacy Notice

About us
Innovation
Products
Partnering
Investors
News & Events
Careers
Contact

Public Relations : pr@transcenta.com

Investor Relations: ir@transcenta.com

Business Development: bd@transcenta.com

Compliance: compliance@transcenta.com

TOP